Xbrane Biopharma AB appoints Dina Jurman, Head of Clinical Affairs, to management team

Press release
2017-10-09

Xbrane Biopharma AB (publ) has appointed Dina Jurman, Head of Clinical Affairs at Xbrane, to its management team. Dina holds a M.Sc. in Biomedicine from Uppsala University and has previously worked as Director Clinical Operations at IRW Consulting AB as well as Clinical Operations Manager consultant at Amgen Sweden. Dina started at Xbrane on 4 September, 2017 and is since 9 October, 2017 a part of Xbrane's management team.

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are located in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3^rd, 2016 under the name Xbrane and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.

For further information, please contact:
Martin Åmark
CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20:30 October 9, 2017.